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Background. Neonatal intubation is a stressful procedure that requires premedication to improve intubation conditions and reduce
stress and adverse physiological responses. Premedication used during the INSURE (INtubation, SURfactant therapy, Extubation)
procedure should have a very short duration of action with restoration of spontaneous breathing within a few minutes. Aims.
To determine the best sedative for intubation during the INSURE procedure by systematic review of the literature. Methods.
We reviewed all relevant studies reporting on premedication, distress, and time to restoration of spontaneous breathing during
the INSURE procedure. Results. This review included 12 studies: two relatively small studies explicitly evaluated the effect of
premedication (propofol and remifentanil) during the INSUREprocedure, both showing good intubation conditions and an average
extubation time of about 20 minutes. Ten studies reporting on fentanyl or morphine provided insufficient information about these
items.Conclusions. Too little is known in the literature to draw a solid conclusion onwhich premedication could be best used during
the INSURE procedure. Both remifentanil and propofol are suitable candidates but dose-finding studies to detect effective nontoxic
doses in newborns with different gestational ages are necessary.
1. Introduction
Endotracheal intubation is a frequently performed procedure
in the neonatal intensive care unit (NICU) [1]. It is a stressful
procedure associated with pain and adverse physiological
responses when the neonate is awake. Adverse effects include
hypoxia, bradycardia, systemic hypertension, and increased
intracranial pressure with a potential risk of intraventricular
hemorrhage, especially in preterm infants [2–6]. Intubation
without the use of premedication may lengthen the proce-
dure, require a greater number of attempts [4–6], and cause
traumatic damage to the face, eyes, tongue, gums, and glottic
structures [6, 7]. With this in mind, clinicians have started
to routinely administer premedication [2–4, 8–11]. However,
there is still no consensus about the best drugs for neonatal
intubations [12, 13].
The most frequent reason for intubation in preterm
neonates is surfactant replacement therapy for respiratory
distress syndrome (RDS). Incidence of RDS is 92% in 24-25
weeks, 88% in 26-27 weeks, 76% in 28-29 weeks, and 57%
in 30-31 weeks. Starting early with nasal continuous positive
airway pressure (nCPAP) can reduce the need for surfactant
replacement therapy in RDS by 50% [14]. Historically, sur-
factant was administered via a tracheal tube during mechan-
ical ventilation. As mechanical ventilation may damage the
pulmonary system and cause bronchopulmonary dysplasia
(BPD), new techniques have been introduced to shorten
duration of mechanical ventilation as much as possible.
In the INSURE (INtubation, SURfactant administration,
immediate Extubation) method infants are endotracheally
intubated only for surfactant administration and are extu-
bated immediately thereafter and put on nCPAP again. A
Cochrane review in 2008 showed that the INSURE method
significantly decreased the need for mechanical ventilation
(relative risk (RR) 0.72, 95% confidence interval (CI) 0.59–
0.87), the incidence of BPD (RR 0.68, 95% CI 0.57–0.79) and
the incidence of air leak syndromes (RR 0.52, 95% CI 0.28–
0.96) [15].
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Intubation in the context of the INSURE procedure still
requires the administration of premedication.However, rapid
recovery of the respiratory drive is essential for the success
of the INSURE procedure. As extubation should take place
within several minutes after surfactant administration, the
sedative agent usedmust have a very short duration of action.
There is no consensus about what agent is most suitable as
premedication for INSUREprocedures.The goal of this paper
is to determine the most appropriate sedative for neonatal
intubation during the INSURE procedure by reviewing the
literature.
2. Methods
Literature searches in Pubmed and EMBASEwere performed
to obtain all publications evaluating the effect of premed-
ication for intubation during the INSURE procedure. We
searched for information about the intubation conditions,
the number of attempts needed for successful intubation,
and mainly the time to awakening and extubation. The initia
lsearch strategy involved the following keywords: “intuba-
tion, intratracheal” (MeSH), “premedication” (MeSH), and
INSURE, with the limit newborn: birth-1 month. This search
strategy revealed only 2 relevant publications.
Therefore we performed an additional search strategy
for all publications describing the INSURE procedure and
screening these publications for the following information:
premedication used, dose of premedication, intubation con-
ditions, number of attempts needed for successful intubation,
time to restoration of sufficient breathing pattern, time to
extubation, time to start nasal respiratory support, INSURE
failure, intractable apnea as a reason for INSURE failure,
and time window between extubation and INSURE failure.
This search strategy involved the following keywords: “pul-
monary surfactants” [MeSH], “respiratory distress syndrome,
newborn” [MeSH], “positive pressure respiration” [MeSH],
“continuous positive airway pressure” [MeSH], “infant, new-
born” [MeSH], and “INSURE” in different combinations.
Because the first publication describing the INSURE pro-
cedure appeared in 1990, publications in the time frame
between January 1990 and June 2013 were sought. Because
reviews describing the INSURE procedure do not usually
provide any new data about premedication and its effects,
we excluded reviews. Reference lists of publications describ-
ing the INSURE procedure were screened for other useful
publications. Publications in the English, Dutch, French,
and German languages were included. The full text of each
report describing the INSUREprocedurewas screened for the
abovementioned information.
3. Results
Theoverall literature search yielded 12 studies suitable for our
review. Only 2 publications, both by Welzing et al., explicitly
evaluated the effect of premedication for intubation during
the INSURE procedure, that is, remifentanil and propofol,
respectively [16, 17]. The search strategy for publications
describing the INSURE procedure revealed 36 publications.
We excluded 24 studies, 5 because they were written in
another language (Danish, Swedish, and Chinese), 2 because
any premedication before intubation clearly was not given,
and 17 because they did not provide any information about
the used premedication. Thus, 10 additional publications
were included, next to both studies of Welzing et al. The
following sedatives were evaluated: remifentanil, propofol,
fentanyl, morphine, and a combination of morphine and
pentobarbital. Characteristics of the studies regarding the
INSURE procedure are summarized in Table 1 and detailed
information about the effects and side-effects of the used
premedication is provided in Table 2.
3.1. Remifentanil. In the study of Welzing et al. a total of
21 preterm infants received 10 𝜇g/kg atropine and 2 𝜇g/kg
remifentanil prior to intubation. Fifteen patients (71%) were
intubated at the first attempt and 6 patients (29%) at the
second attempt. First failed attempts were ascribed to inexpe-
rience of residents in training and not to insufficient sedation.
Intubation conditions were excellent in 14 patients (67%) and
good in 7 patients (33%). No serious side effects occurred.
nCPAP could be started, a mean of 10.9 minutes (range 1–30
minutes) after surfactant administration, and mean time to
extubation was 42.4 minutes (range 1–330 minutes) [16].
3.2. Propofol. A pilot study of Welzing et al. evaluated the
effect of propofol as premedication before intubation during
the INSURE procedure. This pilot was supposed to continue
for 1 year but was stopped prematurely because of significant
problems with arterial hypotension.Thirteen preterm infants
underwent the INSURE procedure and received 10 𝜇g/kg
atropine and 1mg/kg propofol. Intubation was successful at
the first attempt in 9 patients (69%) and at the second attempt
in 4 patients (31%). First failed attempts were ascribed to
inexperience of residents in training. Intubation conditions
were excellent in five, good in six, and inadequate in two
patients, respectively. Propofol gave only a short period of
respiratory depression and nCPAP could be started as amean
of 25 minutes (2 to 120 minutes) after surfactant administra-
tion. One patient needed reintubation after INSURE because
of inadequate respiratory drive. In 5 of 13 patients significant
arterial hypotension was observed [17].
3.3. Morphine. Five of the 10 additionally included publica-
tions concernedmorphinemonotherapy in a dosage of 100 or
200𝜇g/kg [18–22]. The use of Naloxone was optional in most
studies [18, 19, 21], standard practice in one study [22], andnot
mentioned in one study [20].None of these 5 studies provided
details on intubation conditions and number of attempts for
successful intubation. The studies of Van den Berg et al.
and Flor-de-Lima et al. did not address time to restoration
of spontaneous breathing and INSURE failure because of
insufficient breathing or apnea [18, 22]. In the study of
Cherif et al., all patients were extubated within 6.3 ± 1.7
minutes (range 5–12minutes) after surfactant administration.
However, INSURE failed in 35 patients (32.1%) but reasons
for this failure and the time frame between extubation and
INSURE failurewere notmentioned [20]. Verder et al. did not
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mention time to extubation but did mention INSURE failure
in 15 patients (43%): 2 patients could not be extubated after
surfactant administration and another 13 patients had to be
reintubated. In 10 of these 15 patients the reason for INSURE
failure was recurrent apnea. Information regarding the time
frame between extubation and INSURE failure was lacking
[19]. In another study Verder et al. found that 4 patients (7%)
could not be extubated after surfactant administration. In two
patients the reason was intractable apnea, which is a side
effect of morphine. In this study the use of morphine was
optional and the authors did notmention if these two patients
had received morphine [21].
In the study of Bohlin et al., patients received a com-
bination of 200𝜇g/kg morphine and 2mg/kg pentobarbital
prior to intubation. 100 𝜇g/kg Naloxone was administered
to all patients before extubation. Information regarding
intubation conditions, number of attempts, and extubation
time was not provided. Eight patients (19%) could not be
extubated after surfactant administration. This was related
to the premedication in only one patient, who received an
overdose of pentobarbital [23].
3.4. Fentanyl. Four studies used fentanyl as premedication;
two studies at a dose of 0.5–2𝜇g/kg [24, 25], one study at a
dose of 1–3𝜇g/kg [26], and one study at a dose of 0.2mg/kg
[27]. None of these four studies detailed the intubation
conditions, number of intubation attempts, and time to
return of spontaneous breathing and extubation. The studies
of Sandri et al. and Leone et al. also provided no information
about INSURE failure [24, 27]. In the study of Gizzi et al.
INSURE failed in 11 patients (35%) who were extubated to
nasal CPAP. In 4 patients the reason for INSURE failure
was intractable apnea and the time frame between surfactant
administration and INSURE failure was 48.1 hours (range 5–
72 hours). In patients whowere extubated toNIPPV, INSURE
failed in 2 patients (6%) on account of increased oxygen
requirement [25]. Ancora et al. reported INSURE failure in
14 patients (37%), on account of insufficient respiratory drive
in 13 patients. INSURE failure occurred at a mean of 99 hours
(range 1–150 hours) after extubation [26]. None of the studies
reported the necessity of Naloxone therapy after fentanyl.
4. Discussion
Although the need of premedication before neonatal intu-
bation is well recognized, there is no consensus on the
most effective sedative to eliminate pain, discomfort, and
physiologic instability and to provide conditions for rapid and
safe intubations without adverse effects. Moreover, duration
of action must be as short as possible to allow for a sufficient
breathing pattern within several minutes after surfactant
administration, so that extubation can be performed as
quickly as possible (see Figure 1).This review found that only
2 pharmacological studies evaluated the effect of premedi-
cation for the INSURE procedure, that is, remifentanil and
propofol.
Remifentanil, a synthetic opioid, was introduced into
clinical practice in 1996 and is therefore the newest opioid
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Figure 1: Ideal sedation model for the INSURE procedure.
available [28, 29]. Because of hydrolysis by nonspecific
tissue and plasma esterases, metabolism is not dependent
on liver and renal function, and metabolism is not age
related [30–34]. Metabolism produces a metabolite known as
remifentanil acid, which has no clinical significant activity
[29, 31, 32]. This unique pharmacokinetic profile provides
ultrashort action, high predictability, rapid onset and offset
of action, immediate recovery of the clinical effect after
interruption of the administration, a short context-sensitive
half-life and short elimination time not influenced by the
infusion time, and no accumulation of the drug [30, 31].
These positive effects of remifentanil were evident in several
reviewed studies [32–39].
Choong et al. investigated the effect of remifentanil as
premedication in neonatal elective intubations. They found
good intubation conditions (using a seven-point Likert scale)
and few intubation attempts were needed. Mean time to
return of spontaneous respiration in those patients who did
not receive any additional drugs besides remifentanil was
210 seconds [30]. This finding supports our hypothesis that
remifentanil is suitable for the INSURE procedure. In the
study of Welzing et al. remifentanil was also found to be
effective for neonatal intubation. Intubation conditions were
good or excellent in all patients and the vast majority of
patients were intubated at the first attempt [16]. However,
the authors’ conclusions about the very short period of
respiratory depression and early reinstitution of CPAP after
surfactant treatment are debatable. The time to extubation
was rather long (42.4 minutes and still 16.9 minutes after
excluding 3 patients on prolonged endotracheal CPAP for
logistic reasons) and does not perfectly meet the criterion
of immediate extubation. To our opinion it therefore feels
somewhat preliminary to state that remifentanil is an appro-
priate sedative to use as premedication for neonatal intuba-
tion during the INSURE procedure. Reduced clearance of
remifentanil in the first postnatal days could probably explain
the prolonged effect, and it would seem desirable to evaluate
lower remifentanil doses that have not yet been studied.More
research with remifentanil during the INSURE procedure in
a larger group of preterm infants of variable gestational ages is
needed.
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Propofol is a short acting single-use anaesthetic that is
rapid in onset and short in duration and can preserve spon-
taneous respirations [40]. It is a highly lipophilic compound
and exhibits rapid distribution from blood into subcuta-
neous fat and the central nervous system with subsequent
redistribution. Propofol clearancemainly depends on hepatic
blood flow with subsequent metabolism. Although multiple
hepatic and extrahepatic human cytochrome p450 isoforms
are involved in propofol metabolism, glucuronidation is the
major metabolic pathway [41]. A study of Ghanta et al.
found that, with the use of propofol 2.5mg/kg, successful
intubation was reached twice as fast as with the combination
of morphine, atropine, and suxamethonium, fewer attempts
were needed, and patients regained spontaneous movements
twice as fast [12].
Nevertheless, several studies have shown reduced propo-
fol clearance notably in preterm neonates and neonates in the
first 10 days of life, leading to accumulation of the drug dur-
ing continuous infusion and bolus administration. Preterm
neonates and neonates in the first 10 days of life are even
more prone to display reduced clearance. After correcting for
postmenstrual age and postnatal age, there is still extensive
unexplained interindividual variability in propofol clearance
in neonates, making prediction in neonates more difficult
[40–43].
Welzing et al. evaluated the effect of propofol in a dose of
1mg/kg in 13 patients undergoing INSURE. Propofol seemed
to be very suitable and provided excellent or good intubation
conditions in most patients and a very short period of
respiratory depression [17]. We feel, however, that the 25
minutes’ time to extubation is too long. Also, one patient
needed reintubation because of insufficient breathing. Again,
the rather long time to extubation may be explained perhaps
by reduced clearance of propofol in preterm infants in the first
10 days of life which leads to longer duration of the sedative
effect. Dose-finding studies in preterm infants of different
gestational and postnatal ages should be performed to deter-
mine the right dose of propofol for different gestational and
postnatal ages.
Further concerns about propofol in preterm neonates
include the relatively high incidence of side effects, especially
profound hypotension. The pilot study of Welzing et al. was
stopped prematurely because of significant hypotension in
5 patients [17]. The relatively long lasting sedation and high
incidence of hypotension point at excessive propofol doses.
Evidence on the hypotensive side effect of propofol is not
consistent: some studies report relatively high frequencies
of hypotension [40, 44–46], but this is not confirmed by
others [12, 31, 47]. Vanderhaegen et al. studied the cerebral
and systemic hemodynamic effects of propofol in neonates
and found a short lasting decrease in cerebral oxygenation
of several minutes and a decrease in mean arterial blood
pressure up to 1 hour after propofol administration [40].
Possible age-related propofol dose response of neonates
needs further exploration. The adequate propofol doses that
provide good sedation, no hypotension or decreased cerebral
perfusion, and fast restoration of sufficient breathing have
yet to be found. Also, more research on the adequate doses
of propofol for different gestational age groups during the
INSURE procedure is needed. Once known, propofol should
be compared with remifentanil in a randomized controlled
manner, to evaluate which drug would be the best with the
fewest side effects.
Of all other 10 publications describing the INSURE
procedure, only the one by Cherif et al., on morphine,
reported a time to extubation, that is, 6.3 ± 1.7 minutes (range
5–12 minutes) [20]. Based on the PK/PD profile of morphine
in newborns this seems to be quite short and morphine
might not even have reached Pmax, also in view of the fact
that INSURE failed in 32% of patients. This may have been
due to recurrent apnea due to opioid induced respiratory
depression. All other nine studies do not mention time to
awakening and extubation but some of the studies mention
INSURE failure because of intractable apneas [19, 21, 23, 24,
26]. Opioid induced respiratory depression probably was the
cause of these apneas.
Morphine has several limitations, notably delayed onset
and prolonged duration of action, on account of which it is
unsuitable to be used as a sedative in neonatal intubation
[6, 11, 36]. This is confirmed by several studies. Lemyre
et al. performed a randomized placebo controlled trial of
morphine and found no differences between morphine and
placebo in duration of distortion of vital parameters, duration
of the intubation procedure, and number of attempts [48].
Several other studies compared morphine with other pre-
medication regimens and unanimously found that morphine
was less effective, providing worse intubation conditions and
necessitating a greater number of attempts [12, 36, 49]. The
prolonged duration of action of morphine could be antag-
onized with naloxone. However, naloxone also antagonizes
endorphins and results in a direct very distressful condition
and has the potential to cause cardiac arrest, as reported
in an extremely preterm infant and two adult patients [50].
Also, the duration of action of naloxone is much shorter
than that of morphine.Therefore, opioid induced respiratory
depression antagonized with naloxone can easily return after
the effect of naloxone has worn off. All this makes clear that
morphine should not be used as premedication in neonatal
intubation, especially during the INSURE procedure. Short
acting opioids therefore probably are more suitable.
Other short acting drugs or combinations of drugs that
could theoretically be used as rapid sequence induction for
the INSURE procedure, such as midazolam or remifentanil
combined with propofol or with thiopental, have not been
reported in the literature yet [51].
5. Conclusion
In conclusion, propofol and remifentanil both have a very
short onset and duration of action and are in theory the most
suitable candidates for INSURE procedure premedication.
However, only two relatively small studies have evaluated
the effects of propofol and remifentanil in this context and
insufficient data is available about optimal dosing, effects, and
side effects. Therefore, more research including dose-finding
studies and randomized controlled trials that compare dif-
ferent drugs are necessary. Morphine should be considered
8 BioMed Research International
unsuitable for its delayed onset and prolonged period of
action. This literature review revealed too little information
to draw a solid conclusion.
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